Adage Capital Partners GP L.L.C. Lowers Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Adage Capital Partners GP L.L.C. decreased its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 21.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,928,086 shares of the company's stock after selling 807,655 shares during the quarter. Adage Capital Partners GP L.L.C. owned approximately 12.49% of UroGen Pharma worth $31,184,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new stake in UroGen Pharma during the 4th quarter worth approximately $59,000. Oppenheimer & Co. Inc. purchased a new stake in shares of UroGen Pharma in the fourth quarter worth $126,000. Legal & General Group Plc raised its position in shares of UroGen Pharma by 24.6% during the 4th quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock valued at $211,000 after purchasing an additional 3,920 shares during the period. SG Americas Securities LLC lifted its stake in shares of UroGen Pharma by 44.1% during the 4th quarter. SG Americas Securities LLC now owns 20,269 shares of the company's stock valued at $216,000 after buying an additional 6,207 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in UroGen Pharma by 13.6% in the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock worth $242,000 after buying an additional 2,727 shares during the period. 91.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at UroGen Pharma

In related news, insider Mark Schoenberg sold 4,551 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now directly owns 145,666 shares of the company's stock, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the transaction, the general counsel now directly owns 26,468 shares of the company's stock, valued at $294,853.52. The trade was a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Scotiabank assumed coverage on UroGen Pharma in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $55.00 target price on shares of UroGen Pharma in a research note on Monday. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target for the company. D. Boral Capital reiterated a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Monday. Finally, The Goldman Sachs Group dropped their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $32.86.

UroGen Pharma Stock Up 14.1 %

URGN stock traded up $1.39 during trading on Monday, hitting $11.26. 2,322,944 shares of the company's stock traded hands, compared to its average volume of 526,662. The firm has a market capitalization of $519.02 million, a P/E ratio of -3.57 and a beta of 0.80. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma Ltd. has a 1 year low of $8.94 and a 1 year high of $20.70. The business has a fifty day simple moving average of $10.44 and a two-hundred day simple moving average of $11.08.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million. Sell-side analysts anticipate that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.